Remdesivir

Generic name
Remdesivir
Brand name
ATC Code
J05AB16
Compare …

Remdesivir

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

COVID-19 pneumonia requiring oxygen suppletion
  • Intravenous
    • 1 month up to 18 years and < 40 kg
      • Initial dose: 5 mg/kg/day, once only on day 1.
      • Maintenance dose: 2.5 mg/kg/day in 1 dose
      • Duration of treatment:

        max 10 days.

        • Administer in 30-120 minutes

         
COVID-19 infected patients at increased risk of progressing to severe COVID-19
  • Intravenous
    • 1 month up to 18 years and ≥ 40 kg
      • Initial dose: 200 mg/day, once only.
      • Maintenance dose: 100 mg/day in 1 dose
      • Duration of treatment:

        3 days, starting as soon as possible after diagnosis of COVID-19 and within 7 days of the onset of symptoms.

        • Administer in 30-120 minuten.
    • 1 month up to 18 years and ≥ 40 kg
      [3]
      • Initial dose: 200 mg/day, once only.
      • Maintenance dose: 100 mg/day in 1 dose
      • Duration of treatment:

        3 days, starting as soon as possible after diagnosis of COVID-19 and within 7 days of the onset of symptoms.

        • Administer in 30-120 minuten.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: dose adjustment in renal impairment not needed.
GFR <10 ml/min/1.73m2: a general recommendation in renal impairment cannot be given .

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

The side effects in children are consistent with the side effect profile in adults.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Monitoring of transamines and renal function is indicated.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

DIRECT ACTING ANTIVIRALS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB01
J05AB12
J05AB06
J05AB04
J05AB11
J05AB14
Phosphonic acid derivatives
J05AD01
Protease inhibitors
J05AE08
J05AE10
J05AE07
J05AE02
J05AE04
J05AE03
J05AE01
Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF06
J05AF02
J05AF09
J05AF10
J05AF05
J05AF04
J05AF07
J05AF13
J05AF13
J05AF01
Non-nucleoside reverse transcriptase inhibitors
J05AG06
J05AG03
J05AG04
J05AG01
J05AG05
Neuraminidase inhibitors
J05AH02
J05AH01
Antivirals for treatment of HIV infections, combinations
J05AR02
J05AR20
J05AR13
J05AR25
J05AR18
J05AR19
J05AR03
J05AR09
J05AR10
Other antivirals
J05AX28
J05AX12
J05AX07
J05AX09
J05AX08
J05AX24
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS
J05AR02
J05AR20
J05AR13
J05AR25
J05AR18
J05AR19
J05AR03
J05AR09
J05AR10
Integrase inhibitors
J05AJ04
Antivirals for treatment of HCV infections
J05AP54
J05AP57
J05AP51
J05AP08
J05AP55

References

  1. SWAB in collaboration with CIB, NVZA, NVMM, NVII and NVIC, Medicamenteuze behandelopties bij patiënten met COVID-19 (infecties met SARS-CoV-2), https://swab.nl/nl/covid-19, July 3, 2020
  2. Gilead Sciences International Limited, Remdesivir under Emergency Use Authorization, https://www.gilead.com/-/media/files/pdfs/remdesivir/eua-fact-sheet-for-hcps.pdf?la=en&hash=B56F8C441364B7EDA15543F75E8EC88F, Revised: 06/2020
  3. Gilead Sciences Ireland UC, SmPC Veklury (EU/1/20/1459/001) Rev 23, 05-12-2023, www.ema.europa.eu
  4. Lutz JD, et al, Physiologically-Based Pharmacokinetic Modeling of Remdesivir and its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients with COVID-19. , Clin Pharmacol Ther. , 2021, Jan 27, Online ahead of print.
  5. Lutz JD, et al, Physiologically-Based Pharmacokinetic Modeling of Remdesivir and its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients with COVID-19., Clin Pharmacol Ther., 2021, Jan 27, Online ahead of print.

Changes

Therapeutic Drug Monitoring


Overdose